Clinical Trial Update: Treatment of Von Hippel-Lindau (VHL)-Related Hemangioblastoma With PTK787/ZK 222584 [Phase 2]

View source ↗

Summary

Phase 2 clinical trial update evaluating PTK787/ZK 222584 (vatalanib) for Von Hippel-Lindau-related CNS and retinal hemangioblastomas; study completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Cns Hemangioblastoma
• Retinal Hemangioblastoma
• Von Hippel-lindau Disease

Drugs mentioned

• PTK787/ZK 222584 (PTK787/ZK 222584)

Snippet

Sponsor: Novartis Pharmaceuticals | Conditions: Von Hippel-Lindau Disease, CNS Hemangioblastoma | Phase 2 | Status: COMPLETED